Resverlogix Corp.
RVXCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.23M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $29.23 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.03 |
| Beta | 1.06 |
| Outstanding Shares | 329,206,258 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.72 |
|---|---|
| PEG | -0.64 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Resverlogix Corp.
19 employees
CEO: Donald J. McCaffrey
Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bro...